Mark Bachleda
Geen lopende functies
Vermogen: 2 277 $ op 30-04-2024
Profiel
Mark J.
Bachleda worked as a Vice President at Bristol Myers Squibb Co. and as a Vice President-Sales & Account Management at Juno Therapeutics, Inc. He also worked as a Chief Commercial Officer at Galera Therapeutics, Inc. from 2021 to 2023.
Bachleda holds an MBA from the University of California, Berkeley and a doctorate from the University of Illinois.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 21-04-2023 | 11 000 ( 0.02% ) | 2 277 $ | 30-04-2024 |
Eerdere bekende functies van Mark Bachleda
| Bedrijven | Functie | Einde |
|---|---|---|
| GALERA THERAPEUTICS, INC. | Corporate Officer/Principal | 09-08-2023 |
| JUNO THERAPEUTICS INC | Verkoop & Marketing | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Opleiding van Mark Bachleda
| University of Illinois | Doctorate Degree |
| University of California, Berkeley | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| GALERA THERAPEUTICS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
